title: Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
abstract: To explore the clinical implication of activin receptor-like kinase 7 (ALK7) expression in breast cancer, we evaluated its protein level in six kinds of human breast tissue samples, including adjacent normal tissues, adenosis, breast fibroadenoma, ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and lymph node metastases (LNM). Immunohistochemical analyses showed that ALK7 was more frequently and much more intensely expressed in adjacent normal tissues, adenosis, and fibroadenoma tissues than in malignant tissues (DCIS, IDC, and LNM). Furthermore, the ALK7 expression in primary tumors and the corresponding LNM was evaluated in parallel samples from 60 patients with IDC. Results showed that the ALK7 expression status in primary tumors and LNM was concordant in 53 patients (88%), suggesting that ALK7 expression was retained in LNM. Moreover, our results suggested that ALK7 expression inversely correlated with the tumor grade (P=0.009) and clinical stage (P=0.004) in IDC significantly. Finally, the effect of activin-ALK7 pathway on the breast cancer cell growth was elucidated, and results revealed that overexpression of ALK7 could restore the inhibitory effect of activin B on the growth of ALK7-negative breast cancer cell line, ZR-75-30. These findings provide the evidence that the reduction or lack of ALK7 expression may account for the loss of its ligand sensitivity of breast cancer cells, thereby leading to breast tumor progression.
authors.affiliation: School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, People's Republic of China.
authors.forename: Fancai
authors.initials: F
authors.lastname: Zeng
authors.forename: Guoxiong
authors.initials: G
authors.lastname: Xu
authors.forename: Tiejun
authors.initials: T
authors.lastname: Zhou
authors.forename: Chengwan
authors.initials: C
authors.lastname: Yang
authors.forename: Xinyan
authors.initials: X
authors.lastname: Wang
authors.forename: Chun
authors.initials: C
authors.lastname: Peng
authors.forename: Hong
authors.initials: H
authors.lastname: Zhou
mesh_terms: D030201:Activin Receptors, Type I / Q000032:analysis / Q000502:physiology*; D028341:Activins / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology*; D045744:Cell Line, Tumor; D018450:Disease Progression; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics
chemical_list: D018125:Receptors, Transforming Growth Factor beta; C044147:activin B; D028341:Activins; D017346:Protein Serine-Threonine Kinases; C424205:ACVR1C protein, human; D030201:Activin Receptors, Type I; D000077294:Receptor, Transforming Growth Factor-beta Type II
references.citation: J Clin Invest. 2003 Aug;112(4):575-87
references.pmid: 12925698
references.citation: APMIS. 1995 Jan;103(1):20-4
references.pmid: 7695887
references.citation: Lab Invest. 2010 Sep;90(9):1339-45
references.pmid: 20531292
references.citation: J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):117-26
references.pmid: 21475961
references.citation: Histopathology. 2000 Feb;36(2):168-77
references.pmid: 10672063
references.citation: Cell. 2008 Jul 25;134(2):215-30
references.pmid: 18662538
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Cancer Res. 1997 May 15;57(10):2071-6
references.pmid: 9158007
references.citation: Genes Dev. 2001 Aug 1;15(15):2010-22
references.pmid: 11485994
references.citation: J Biol Chem. 1996 Nov 29;271(48):30603-9
references.pmid: 8940033
references.citation: Cancer Res. 2003 Jul 1;63(13):3783-90
references.pmid: 12839974
references.citation: Mol Cancer Res. 2006 Apr;4(4):235-46
references.pmid: 16603637
references.citation: Cell Growth Differ. 1998 Feb;9(2):185-93
references.pmid: 9486855
references.citation: Cell Growth Differ. 1995 Sep;6(9):1151-61
references.pmid: 8519692
references.citation: Mol Cell Endocrinol. 2004 May 31;220(1-2):59-65
references.pmid: 15196700
references.citation: Clin Cancer Res. 1996 Aug;2(8):1255-61
references.pmid: 9816295
references.citation: J Biol Chem. 2001 Feb 16;276(7):5140-6
references.pmid: 11084022
references.citation: Mol Cell Endocrinol. 2004 Oct 15;225(1-2):77-82
references.pmid: 15451571
references.citation: Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):41-58
references.pmid: 16310402
references.citation: Br J Cancer. 2000 Jan;82(1):112-7
references.pmid: 10638976
references.citation: Histol Histopathol. 2009 Jun;24(6):675-82
references.pmid: 19337966
references.citation: Diabetologia. 2006 Mar;49(3):506-18
references.pmid: 16440210
references.citation: J Clin Endocrinol Metab. 2002 Oct;87(10):4741-6
references.pmid: 12364468
references.citation: Clin Cancer Res. 1998 Jul;4(7):1625-30
references.pmid: 9676836
references.citation: J Biol Chem. 2004 Jul 2;279(27):28458-65
references.pmid: 15107418
references.citation: Urology. 2003 May;61(5):1072-7
references.pmid: 12736050
references.citation: Reproduction. 2007 May;133(5):847-53
references.pmid: 17616715
references.citation: J Biol Chem. 2004 Jul 23;279(30):31277-86
references.pmid: 15150278
references.citation: J Clin Endocrinol Metab. 2004 Nov;89(11):5523-34
references.pmid: 15531507
references.citation: J Natl Cancer Inst. 1999 Dec 15;91(24):2096-101
references.pmid: 10601380